Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Moves into MicroRNA, Signs Preclinical Platform Deal with Regulus

This article was originally published in The Pink Sheet Daily

Executive Summary

With $25 million upfront, $10 million in equity and hundreds of millions of dollars in possible milestones, Sanofi makes a significant early bet on the latest RNA-based therapeutic class to emerge.
Advertisement

Related Content

MicroRNA Momentum Builds, But Will Big Pharma Embrace It?
AstraZeneca Taps Regulus For microRNA Drug Development
Sanofi Holds Brainstorming Sessions To Fuel Its Therapeutic Strategy Units
Sanofi Holds Brainstorming Sessions To Fuel Its Therapeutic Strategy Units
Start-Up Quarterly Statistics, Q2 2010
GSK Doubles Up With Regulus, Signing New Collaboration For HCV Therapeutics
Regulus Is On The Launch “Platform” With $20M Series A Financing
Novartis Opens Door to Broad Dealmaking in RNAi

Topics

Advertisement
UsernamePublicRestriction

Register

PS070796

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel